

## CREDIT OPINION

24 August 2020

Update

✓ Rate this Research

### RATINGS

#### Essity Aktiebolag

Domicile	Sweden
Long Term Rating	Baa1
Type	LT Issuer Rating - Fgn Curr
Outlook	Stable

Please see the [ratings section](#) at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date.

### Contacts

Dirk Steinicke +49.69.70730.949  
AVP Mgr-Rtgs & Research Sup  
dirk.steinicke@moody.com

## Essity Aktiebolag

Update following H1 2020 results


### Summary

The Baa1/P-2 ratings of [Essity Aktiebolag](#) (Essity) with a stable outlook primarily reflect the company's large scale, with revenue of SEK128 billion for the 12 months that ended June 2020 (around \$13 billion), and a broad product portfolio; its leading market positions, with well-recognised brands and a good track record of innovation; its global footprint, with the faster-growing emerging markets representing roughly one-third of its revenue; the fairly good underlying growth and the stable demand for its products; and its financial policies, which are aimed at protecting its solid investment-grade rating, and a track record of significant positive free cash flow (FCF) that the company can use for deleveraging, if needed.

Essity's ratings are primarily constrained by the company's exposure to volatile input costs, pulp in particular, which can be passed through only with a significant delay; its somewhat below-average profitability compared with that of most of its similarly rated peers, such as [Kimberly-Clark](#) (K-C, A2 stable) or [Procter & Gamble](#) (P&G, Aa3 stable), with a Moody's-adjusted EBIT margin of 13.5% for the 12 months that ended June 2020; its strained operating environment because of the coronavirus pandemic-related lockdowns; and a certain degree of debt-funded M&A risk, which, however, falls within the company's commitment to maintaining a solid investment-grade rating.

Exhibit 1

We expect Essity's leverage to remain well below our downgrade trigger after the integration of BSN Medical



All ratios are based on 'Adjusted' financial data and incorporate Moody's Global Standard Adjustments for Non-Financial Corporations.

Forward view represents Moody's view and does not incorporate any material divestments and acquisitions (following the integration of BSN Medical).

Source: Moody's Financial Metrics™

## Credit strengths

- » A strong business profile, with a broad portfolio of well-positioned global (Tork and Tena) and regional brands
- » Fairly good underlying growth and stable demand for most of its products even after the outbreak of the coronavirus pandemic
- » A financial policy that is aimed at protecting its solid investment-grade rating

## Credit challenges

- » Exposure to volatile input costs such as pulp and recycled paper
- » Ongoing need for innovation in the personal care and tissue businesses to preserve pricing levels
- » Professional care product demand to be hurt by the coronavirus pandemic-related lockdowns
- » Event risks, such as debt-funded M&A or shareholder-friendly actions

## Rating outlook

The stable outlook reflects our expectation that Essity will continue to operate with solid credit metrics that are commensurate with the Baa1 ratings during next 12-18 months, with its Moody's-adjusted debt/EBITDA remaining well below 3.0x.

This publication does not announce a credit rating action. For any credit ratings referenced in this publication, please see the ratings tab on the issuer/entity page on [www.moody's.com](http://www.moody's.com) for the most updated credit rating action information and rating history.

## Factors that could lead to an upgrade

- » EBIT margin consistently above 12% in the company's business areas
- » Retained cash flow/net debt above 25%
- » Debt/EBITDA well below 2.5x
- » Continued positive FCF, which is applied towards debt reduction

## Factors that could lead to a downgrade

- » A decline in the company's EBIT margin to below 9%
- » Retained cash flow/net debt falling below 20% on a sustained basis
- » Failure to maintain debt/EBITDA below 3x
- » FCF turning negative
- » Erosion of the company's solid liquidity

## Key indicators

Exhibit 2

### Essity Aktiebolag

	12/31/2016	12/31/2017	12/31/2018	12/31/2019	6/30/2020(L)	Next 12 - 18 months
Revenue (USD Billion)	\$11.8	\$12.8	\$13.6	\$13.6	\$13.3	\$13.5 - \$14.5
EBITA Margin	11.3%	12.2%	10.5%	12.2%	14.4%	13% - 14%
Debt / EBITDA	2.5x	3.2x	3.3x	2.5x	2.1x	2.0x - 2.5x
RCF / Net Debt	28.0%	25.1%	20.5%	22.2%	33.8%	25% - 30%
EBITA / Interest Expense	9.2x	9.1x	8.2x	10.2x	12.7x	11.5x - 13x


All ratios are based on 'Adjusted' financial data and incorporate Moody's Global Standard Adjustments for Non-Financial Corporations. This represents Moody's forward view, not the view of the issuer, and does not incorporate significant acquisitions and divestitures.

Source: Moody's Financial Metrics™

## Profile


Headquartered in Stockholm, Sweden, Essity Aktiebolag (Essity) is one of the leading global hygiene and health companies, with sales of SEK128 billion for the 12 months that ended June 2020 (around \$13 billion). The company develops, produces and sells a wide range of products, including incontinence products, baby diapers, feminine-care products, consumer tissue, away-from-home tissue, and products for wound care, compression therapy and orthopaedics. With a workforce of roughly 46,000 employees, Essity operates in about 150 countries worldwide under a number of well-recognised brands. Essity was formed in 2016 and spun off in June 2017 from Svenska Cellulosa Aktiebolaget (SCA). The company is listed on the Stockholm Stock Exchange, with a market capitalisation of around SEK206 billion as of 13 August 2020.

Exhibit 3  
Revenue split by product  
As of full year 2019



Source: Essity

Exhibit 4  
Revenue split by geography  
As of full year 2019



Source: Essity

## Detailed credit considerations

### Wide product portfolio, with a number of leading positions globally

Essity's Baa1/P-2 ratings reflect the fact that with sales of close to SEK130 billion, the company is one of the leading global hygiene and health companies, active in around 150 countries. Among others, the company is the global leader in incontinence products under the Tena brand and in professional hygiene under the Tork brand. In addition, the company has strong brands and market positions within the markets for baby diapers, feminine care and consumer tissue, as well as regional and global brands. Essity also has leading market positions in wound care, compression therapy and orthopaedics, with brands such as Jobst and Leukoplast. Overall, the company holds the first or second position within at least one product segment in around 90 countries.

Exhibit 5  
Overview of market positions and key brands


	Global	Europe	North America	Latin America	Asia	Key Brands
Incontinence Products	#1	#1	#4	#1	#3	Tena
Baby Care	#5	#2	n.a.	#6	#6	Drypers, Pequenín, Libero, Lotus Baby
Feminine Care	#6	#3	n.a.	#1	#10	Libresse, Saba, Nosotras, Bodyform, Nana
Medical Solutions	#4	#1	#12	#3	#2	Jobst, Leukoplast, Cutimed, Delta-Cast, Actimove
Consumer Tissue	#2	#1	n.a.	#3	#1	Edet, Lotus, Regio, Tempo, Vinda, Zewa, Plenty
Professional Hygiene	#1	#1	#2	#4	#3	Tork

Source: Essity

The personal care and tissue markets are fairly competitive, and subject to periods of temporary oversupply, which require producers to continuously focus on innovation to protect brand strength and optimise costs. In the tissue business, which is generally more competitive and less profitable, Essity competes primarily with [Georgia-Pacific LLC](#) (A3 stable), Hengan, K-C and Sofidel. In the personal care business, Essity's key competitors are K-C, P&G and Unicharm. In April 2017, following the debt-funded acquisition of BSN Medical for €2.7 billion, the company entered the market for medical devices with low technology content, such as wound care and compression therapy, which benefits from robust and stable demand and above-average profitability.

We expect Essity to focus on growing its personal care and medical device product offerings while further increasing the efficiency of its tissue operations. This strategy will help narrow the profitability gap with the company's more-profitable competitors, especially K-C and P&G, which benefit from a higher share of the more-profitable personal care business and the generally more-profitable US market.

Exhibit 6

**Essity's margins have been below those of its main competitors, but the gap narrowed in 2019****Moody's-adjusted EBIT margin**

All ratios are based on 'Adjusted' financial data and incorporate Moody's Global Standard Adjustments for Non-Financial Corporations.

Source: Moody's Financial Metrics™

**Good underlying demand growth, especially in emerging markets**

Essity benefits from the underlying growth in demand for its products, supported by megatrends such as population growth and higher disposable income, as well as the increased prevalence of people with chronic diseases. While mature markets continue to experience modest annual growth in the low-single-digit percentages, the growth potential in emerging markets is substantial, and we estimate the annual growth in these markets to be in the high-single-digit percentages. This is because the per capita consumption of tissue and personal care products in emerging markets is significantly lower in an environment where living standards are rapidly improving.


To benefit from this development, Essity had focused on growing its presence in emerging markets over the past decade. This was done both organically and through M&A, most recently through an acquisition of a majority stake in the Hong-Kong-based tissue company Vinda in November 2013. Currently, emerging markets represent roughly one-third of the revenue, and we expect this share to increase further.

**Profitability has exposure to volatile input costs**

The demand for Essity products has historically been fairly good stable through the cycle. Even during the 2008-09 global economic downturn, which was unprecedented in its magnitude, the company hardly faced any decline in organic sales, and margins for both the tissue and personal care businesses, the latter one in particular, remained robust. Nevertheless, the coronavirus pandemic severely affected demand for professional hygiene products because of the resulting lockdown measures taken by governments. This prevented consumers from purchasing services as usual because larger events were cancelled and restaurants were shut down. However, the continued increase in demand for tissue products signals an ongoing megatrend towards increased use of hygiene products.

The profitability for both the tissue and personal care operations has been fairly stable over the last decade, which also indicates Essity's ability to manage its key input costs. Some of the input costs, such as pulp (17% of total operating expenses at the group level in 2019) and recycled paper (4%), have fairly high volatility, and price increases can be typically passed on to customers only with delays of up to one year. Even in an environment of substantially increasing pulp prices in 2017 and the first half of 2018, the company delivered a fairly robust performance, with less volatility than that of its key tissue peers in Europe.

Exhibit 7

**Essity has had fairly stable demand patterns and profitability through the cycle**

Change in reporting segments in 2017 with retrospective changes until 2015. The segment previously named tissue is now split into professional hygiene and consumer tissue. Data as reported by the company (that is, without Moody's adjustments).

Sources: Essity financial reports and former Svenska Cellulosa Aktiebolaget segmental reporting

**M&A risk, but within the limits of Essity's financial policies, which target a solid investment-grade rating**

Essity's financial policies are centred around its commitment to retain a solid investment-grade rating, which drives its capital allocation priorities, including dividend payouts as well as M&A. Although we believe that in the next couple of years the company will continue to complement organic growth with M&A, especially in the area of medical devices with low technology content, where the market is still relatively fragmented, at this point, there is still limited capacity for debt-funded growth. We expect the company to refrain from any major M&A until it improves its credit metrics to the levels commensurate with a Baa1 rating.

Following the acquisition of BSN Medical in April 2017, Essity's leverage remained high, with Moody's-adjusted debt/EBITDA above 3x during 2017 and 2018 and improving to below 3x in second half of 2019, positioning the company weakly in the Baa1 category for some time. However, we believe that Essity will be willing and able to operate with a leverage of below 3.0x through the cycle, supported by both EBITDA growth, as the company continues to pass through high pulp prices to its customers, and actual debt repayments. Taking into consideration Essity's capital spending of 5%–6% of sales and dividends typically of around 50% of net income, we expect the company to continue to generate positive FCF in the high-single-digit percentages of Moody's-adjusted gross debt, which could be used for debt repayments. We will assess further smaller acquisitions within the limits of the company's FCF on a case-by-case basis.


**Liquidity analysis**

We consider Essity's liquidity good, primarily based on our expectation that the company will continue to generate significant positive FCF over the next four to six quarters. As of the end of June 2020, the company reported around SEK5.5 billion of cash and cash equivalents, roughly one-third of those in countries with currency restrictions. In addition, the company has access to various largely undrawn credit facilities, totalling roughly SEK21 billion, consisting primarily of two syndicated facilities, each of €1.0 billion, maturing in 2025 with the later one having an extension option to 2026. The facilities are of high quality, without material adverse change clauses and other conditionality language, and have also served as backstop facilities for the company's commercial paper programme, which has been a central source of Essity's short-term funding needs. As of the end of June 2020, the company reported roughly SEK8.4 billion in short-term debt, which includes around SEK5 billion in Swedish krona and euro bonds. The company's maturity profile is generally well spread, with an average maturity of around four years.

Exhibit 8

**Essity's debt maturity profile is generally well spread**

As of 30 June 2020



Source: Essity

**Environmental, social and governance considerations**

Despite the fact that the pulp and paper industry is a fairly large consumer of energy and water in the production processes, with occasional environmental incidents, we score it as moderate risk in our [Environmental risks heat map](#). This score means that we believe that the industry's exposure to environmental risk is broadly manageable, or it could be material to the credit quality in the medium to long term (five or more years).

Sustainability is one of the company's strategic priorities as the global awareness about the issue increases. Therefore, Essity promotes sustainable consumption by being innovative in how it meets the needs of its customers, and aims to develop solutions for a sustainable and circular society. The company strives to reduce environmental impact and resource consumption throughout the life cycle of its products and services.

**Methodology and scorecard**

The principal methodology used in rating Essity is the [Global Packaged Goods](#) rating methodology. The methodology grid indicates a weak A3 rating for the metrics achieved for the 12 months that ended June 2020, as well as for our 12-18-month forward-looking view. The one-notch difference is mainly attributed to a weak positioning of Essity in the A category for the Geographic Diversification, Category Assessment, relatively low profit margin and Financial Policy subfactors.

Exhibit 9

## Rating factors

Essity Aktiebolag

Consumer Packaged Goods Industry Scorecard [1][2]			Current LTM 6/30/2020		Moody's 12-18 Month Forward View As of 8/13/2020 [3]	
Factor 1 : Scale (20%)	Measure	Score	Measure	Score	Measure	Score
a) Revenue (USD Billion)	\$13.3	A	\$13.5 - \$14.5	A		
<b>Factor 2 : Business Profile (30%)</b>						
a) Geographic Diversification	A	A	A	A		
b) Segmental Diversification	Baa	Baa	Baa	Baa		
c) Market Position	A	A	A	A		
d) Category Assessment	A	A	A	A		
<b>Factor 3 : Profitability (10%)</b>						
a) EBITA Margin	14.4%	Ba	13% - 14%	Ba		
<b>Factor 4 : Leverage and Coverage (25%)</b>						
a) Debt / EBITDA	2.1x	A	2x - 2.5x	A		
b) RCF / Net Debt	33.8%	Baa	25% - 30%	Baa		
c) EBITA / Interest Expense	12.7x	Aa	11.5x - 13x	A		
<b>Factor 5 : Financial Policy (15%)</b>						
a) Financial Policy	A	A	A	A		
<b>Rating:</b>						
a) Scorecard-Indicated Outcome		A3		A3		
b) Actual Rating Assigned						Baa1

All ratios are based on 'Adjusted' financial data and incorporate Moody's Global Standard Adjustments for Non-Financial Corporations. This represents Moody's forward view, not the view of the issuer, and does not incorporate significant acquisitions and divestitures.

Source: Moody's Financial Metrics™

## Ratings

Exhibit 10

Category	Moody's Rating
<b>ESSITY AKTIEBOLAG</b>	
Outlook	Stable
Issuer Rating	Baa1
Senior Unsecured	Baa1
ST Issuer Rating	P-2

Source: Moody's Investors Service



Exhibit 11

## Peer comparison

(in US millions)	Essity Aktiebolag Baa1 Stable			Kimberly-Clark Corporation A2 Stable			Procter & Gamble Company (The) Aa3 Stable		
	FYE Dec-18	FYE Dec-19	LTM Jun-20	FYE Dec-18	FYE Dec-19	LTM Jun-20	FYE Jun-18	FYE Jun-19	LTM Mar-20
Revenue	\$13,649	\$13,649	\$13,324	\$18,486	\$18,450	\$18,844	\$66,832	\$67,684	\$70,346
EBITDA	\$2,125	\$2,335	\$2,584	\$4,412	\$4,387	\$4,713	\$17,449	\$17,799	\$19,698
Total Debt	\$6,805	\$5,865	\$5,734	\$8,648	\$8,424	\$8,750	\$40,156	\$39,430	\$45,132
Cash & Cash Equiv.	\$348	\$313	\$590	\$539	\$442	\$1,448	\$2,569	\$4,239	\$15,393
EBIT Margin	9.7%	11.3%	13.5%	17.8%	18.0%	19.9%	21.4%	21.8%	23.3%
EBIT / Int. Exp.	7.5x	9.5x	11.9x	10.5x	11.5x	13.3x	19.2x	20.7x	27.3x
Debt / EBITDA	3.3x	2.5x	2.1x	2.0x	1.9x	1.9x	2.3x	2.2x	2.3x
RCF / Net Debt	20.5%	22.2%	33.8%	16.9%	22.2%	27.9%	11.7%	20.8%	27.9%
FCF / Debt	3.0%	14.9%	24.8%	9.7%	1.8%	16.2%	9.9%	11.2%	12.9%

All ratios are based on 'Adjusted' financial data and incorporate Moody's Global Standard Adjustments for Non-Financial Corporations.

Source: Moody's Financial Metrics™

Exhibit 12

## Reconciliation of debt

(in SEK Millions)	FYE Dec-15	FYE Dec-16	FYE Dec-17	FYE Dec-18	FYE Dec-19	LTM Ending Jun-20
<b>As Reported Debt</b>	<b>34,008</b>	<b>36,149</b>	<b>54,124</b>	<b>53,742</b>	<b>51,227</b>	<b>49,749</b>
Pensions	2,917	4,662	3,804	3,830	4,133	4,133
Operating Leases	2,043	2,626	2,328	3,334	0	0
Non-Standard Adjustments	-977	-673	-195	-570	-461	-461
<b>Moody's-Adjusted Debt</b>	<b>37,991</b>	<b>42,764</b>	<b>60,061</b>	<b>60,336</b>	<b>54,899</b>	<b>53,421</b>

Source: Moody's Financial Metrics™

Exhibit 13

## Reconciliation of EBITDA

(in SEK Millions)	FYE Dec-15	FYE Dec-16	FYE Dec-17	FYE Dec-18	FYE Dec-19	LTM Ending Jun-20
<b>As Reported EBITDA</b>	<b>15,552</b>	<b>14,809</b>	<b>18,036</b>	<b>17,500</b>	<b>21,941</b>	<b>24,777</b>
Pensions	149	134	-14	10	21	21
Operating Leases	681	696	776	980	0	0
Unusual	-736	1,346	230	20	160	181
Non-Standard Adjustments	-198	-157	-169	-63	-60	-86
<b>Moody's-Adjusted EBITDA</b>	<b>15,448</b>	<b>16,828</b>	<b>18,859</b>	<b>18,447</b>	<b>22,062</b>	<b>24,893</b>

We define EBITDA as pretax income + gross interest expense + depreciation and amortisation.

Source: Moody's Financial Metrics™

Exhibit 14

## Overview of key metrics

	FYE Dec-15	FYE Dec-16	FYE Dec-17	FYE Dec-18	FYE Dec-19	LTM Ending Jun-20
<b>INCOME STATEMENT</b>						
Revenue	\$11,688.2	\$11,841.1	\$12,807.6	\$13,648.5	\$13,649.3	\$13,324.2
EBITDA	\$1,832.7	\$1,968.2	\$2,210.6	\$2,124.7	\$2,334.8	\$2,583.8
EBIT	\$1,195.4	\$1,296.2	\$1,457.6	\$1,317.9	\$1,543.5	\$1,800.6
Interest Expense	\$152.4	\$145.6	\$172.1	\$175.4	\$163.0	\$151.5
<b>BALANCE SHEET</b>						
Cash & Cash Equivalents	\$577.7	\$471.8	\$532.8	\$347.5	\$312.8	\$590.3
Total Debt	\$4,506.4	\$4,707.3	\$7,335.6	\$6,805.5	\$5,864.6	\$5,733.9
Net Debt	\$3,928.7	\$4,235.5	\$6,802.9	\$6,457.9	\$5,551.8	\$5,143.5
<b>CASH FLOW</b>						
Capex = Capital Expenditures	\$740.3	\$806.0	\$799.2	\$888.2	\$713.9	\$656.2
Funds from Operations	\$1,430.0	\$1,283.6	\$1,674.3	\$1,859.9	\$1,686.6	\$1,701.7
Dividends	\$25.6	\$22.2	\$33.4	\$510.8	\$462.9	\$21.4
Retained Cash Flow	\$1,404.3	\$1,261.4	\$1,640.9	\$1,349.0	\$1,223.7	\$1,680.3
RCF / Net Debt	35.7%	28.0%	25.1%	20.5%	22.2%	33.8%
Free Cash Flow (FCF)	\$579.6	\$730.9	\$736.6	\$209.5	\$867.0	\$1,376.2
FCF / Debt	12.9%	14.6%	10.5%	3.0%	14.9%	24.8%
<b>PROFITABILITY</b>						
% Change in Sales (YoY)	12.0%	2.8%	7.9%	8.5%	8.8%	4.0%
EBIT Margin %	10.2%	10.9%	11.4%	9.7%	11.3%	13.5%
EBITDA Margin %	15.7%	16.6%	17.3%	15.6%	17.1%	19.4%
<b>INTEREST COVERAGE</b>						
EBIT / Interest Expense	7.8x	8.9x	8.5x	7.5x	9.5x	11.9x
EBITDA / Interest Expense	12.0x	13.5x	12.8x	12.1x	14.3x	17.1x
(EBITDA - CAPEX) / Interest Expense	7.2x	8.0x	8.2x	7.0x	9.9x	12.7x
<b>LEVERAGE</b>						
Debt / EBITDA	2.5x	2.5x	3.2x	3.3x	2.5x	2.1x
Debt / (EBITDA - CAPEX)	4.1x	4.3x	5.0x	5.6x	3.6x	2.9x
Net Debt / EBITDA	2.1x	2.3x	3.0x	3.1x	2.4x	1.9x

All ratios are based on 'Adjusted' financial data and incorporate Moody's Global Standard Adjustments for Non-Financial Corporations.

Source: Moody's Financial Metrics™

© 2020 Moody's Corporation, Moody's Investors Service, Inc., Moody's Analytics, Inc. and/or their licensors and affiliates (collectively, "MOODY'S"). All rights reserved.

CREDIT RATINGS ISSUED BY MOODY'S INVESTORS SERVICE, INC. AND/OR ITS CREDIT RATINGS AFFILIATES ARE MOODY'S CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND MATERIALS, PRODUCTS, SERVICES AND INFORMATION PUBLISHED BY MOODY'S (COLLECTIVELY, "PUBLICATIONS") MAY INCLUDE SUCH CURRENT OPINIONS. MOODY'S INVESTORS SERVICE DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY MAY NOT MEET ITS CONTRACTUAL FINANCIAL OBLIGATIONS AS THEY COME DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT OR IMPAIRMENT. SEE MOODY'S RATING SYMBOLS AND DEFINITIONS PUBLICATION FOR INFORMATION ON THE TYPES OF CONTRACTUAL FINANCIAL OBLIGATIONS ADDRESSED BY MOODY'S INVESTORS SERVICE CREDIT RATINGS. CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK, OR PRICE VOLATILITY. CREDIT RATINGS, NON-CREDIT ASSESSMENTS ("ASSESSMENTS"), AND OTHER OPINIONS INCLUDED IN MOODY'S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACT. MOODY'S PUBLICATIONS MAY ALSO INCLUDE QUANTITATIVE MODEL-BASED ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY'S ANALYTICS, INC. AND/OR ITS AFFILIATES. MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES. MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS DO NOT COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY'S ISSUES ITS CREDIT RATINGS, ASSESSMENTS AND OTHER OPINIONS AND PUBLISHES ITS PUBLICATIONS WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL, WITH DUE CARE, MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE.

MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS, AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS OR PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER. ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT MOODY'S PRIOR WRITTEN CONSENT.

MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY ANY PERSON AS A BENCHMARK AS THAT TERM IS DEFINED FOR REGULATORY PURPOSES AND MUST NOT BE USED IN ANY WAY THAT COULD RESULT IN THEM BEING CONSIDERED A BENCHMARK.

All information contained herein is obtained by MOODY'S from sources believed by it to be accurate and reliable. Because of the possibility of human or mechanical error as well as other factors, however, all information contained herein is provided "AS IS" without warranty of any kind. MOODY'S adopts all necessary measures so that the information it uses in assigning a credit rating is of sufficient quality and from sources MOODY'S considers to be reliable including, when appropriate, independent third-party sources. However, MOODY'S is not an auditor and cannot in every instance independently verify or validate information received in the rating process or in preparing its Publications.

To the extent permitted by law, MOODY'S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability to any person or entity for any indirect, special, consequential, or incidental losses or damages whatsoever arising from or in connection with the information contained herein or the use of or inability to use any such information, even if MOODY'S or any of its directors, officers, employees, agents, representatives, licensors or suppliers is advised in advance of the possibility of such losses or damages, including but not limited to: (a) any loss of present or prospective profits or (b) any loss or damage arising where the relevant financial instrument is not the subject of a particular credit rating assigned by MOODY'S.

To the extent permitted by law, MOODY'S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability for any direct or compensatory losses or damages caused to any person or entity, including but not limited to by any negligence (but excluding fraud, willful misconduct or any other type of liability that, for the avoidance of doubt, by law cannot be excluded) on the part of, or any contingency within or beyond the control of, MOODY'S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising from or in connection with the information contained herein or the use of or inability to use any such information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY CREDIT RATING, ASSESSMENT, OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY'S IN ANY FORM OR MANNER WHATSOEVER.

Moody's Investors Service, Inc., a wholly-owned credit rating agency subsidiary of Moody's Corporation ("MCO"), hereby discloses that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by Moody's Investors Service, Inc. have, prior to assignment of any credit rating, agreed to pay to Moody's Investors Service, Inc. for credit ratings opinions and services rendered by it fees ranging from \$1,000 to approximately \$2,700,000. MCO and Moody's Investors Service also maintain policies and procedures to address the independence of Moody's Investors Service credit ratings and credit rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities who hold credit ratings from Moody's Investors Service and have also publicly reported to the SEC an ownership interest in MCO of more than 5%, is posted annually at [www.moody.com](http://www.moody.com) under the heading "Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy."

Additional terms for Australia only: Any publication into Australia of this document is pursuant to the Australian Financial Services License of MOODY'S affiliate, Moody's Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody's Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (as applicable). This document is intended to be provided only to "wholesale clients" within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from within Australia, you represent to MOODY'S that you are, or are accessing the document as a representative of, a "wholesale client" and that neither you nor the entity you represent will directly or indirectly disseminate this document or its contents to "retail clients" within the meaning of section 761G of the Corporations Act 2001. MOODY'S credit rating is an opinion as to the creditworthiness of a debt obligation of the issuer, not on the equity securities of the issuer or any form of security that is available to retail investors.

Additional terms for Japan only: Moody's Japan K.K. ("MJKK") is a wholly-owned credit rating agency subsidiary of Moody's Group Japan G.K., which is wholly-owned by Moody's Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody's SF Japan K.K. ("MSFJ") is a wholly-owned credit rating agency subsidiary of MJKK. MSFJ is not a Nationally Recognized Statistical Rating Organization ("NRSRO"). Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJKK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJKK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MJKK or MSFJ (as applicable) have, prior to assignment of any credit rating, agreed to pay to MJKK or MSFJ (as applicable) for credit ratings opinions and services rendered by it fees ranging from JPY125,000 to approximately JPY250,000,000.

MJKK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.